HEMO 2 life® improves renal function independent of cold ischemia time in kidney recipients: A comparison with a large multicenter prospective cohort study - Ischémie Reperfusion en Transplantation d’Organes Mécanismes et Innovations Thérapeutiques Accéder directement au contenu
Article Dans Une Revue Artificial Organs Année : 2021

HEMO 2 life® improves renal function independent of cold ischemia time in kidney recipients: A comparison with a large multicenter prospective cohort study

Résumé

M101 is an extracellular hemoglobin isolated from a marine lugworm and is present in the medical device HEMO2 life®. The clinical investigation OXYOP was a paired kidney analysis (n = 60) designed to evaluate the safety and performance of HEMO2 life® used as an additive to preservation solution in renal transplantation. The secondary efficacy endpoints showed less delayed graft function (DGF) and better renal function in the HEMO2 life® group but due to the study design cold ischemia time (CIT) was longer in the contralateral kidneys.

Domaines

Immunologie
Fichier non déposé

Dates et versions

hal-03608474 , version 1 (14-03-2022)

Identifiants

Citer

Yannick Le Meur, Eric Delpy, Felix Renard, Thierry Hauet, Lionel Badet, et al.. HEMO 2 life® improves renal function independent of cold ischemia time in kidney recipients: A comparison with a large multicenter prospective cohort study. Artificial Organs, 2021, ⟨10.1111/aor.14141⟩. ⟨hal-03608474⟩
40 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More